Grants and Awards

One-year period ending December 31, 2017 . Click on a title to read more.
Awards information as defined in UW SAGE.
Molecular basis of altered drug metabolism during pregnancy
Isoherranen, Nina , Pharmaceutics
Award Date: 12/21/2017
Sponsor: University of Illinois, Chicago Amount: $7750
Abstract
For the studies proposed in this application, in years 4 and 5 we will conduct all the retinoic acid, retinol, retinyl ester and RBP4 measurements in the human plasma and serum samples using our validated and sensitive liquid chromatography mass spectrometry methods to aid in determining the role of retinoids in altering CYP2D6 expression during pregnancy. We will be responsible for all sample preparation and LC-MS/MS analysis. We will also prepare the quantitative reports of the results generated from the above studies to facilitate publication of the results.
Personnel
Isoherranen, Nina, Principal Investigator, Associate Professor, Pharmaceutics • Kirkwood, Jay, Other, Research Scientist/engineer 2, Pharmaceutics • Royall, Frederick, Administrative Contact, Grants And Contracts Manager/specialist, Pharmaceutics • Royall, Frederick, Budget Contact, Grants and Contracts Manager/Specialist, Pharmaceutics • Royall, Frederick, eGC1 Preparer, Grants and Contracts Manager/Specialist, Pharmaceutics • Royall, Frederick, Budget Preparer, Grants and Contracts Manager/Specialist, Pharmaceutics
Competing Revision - Precision Medicine and Oral Anticoagulants
Thummel, Kenneth E. , Pharmaceutics
Award Date: 12/19/2017
Sponsor: National Institute of General Medical Sciences (NIGMS) Amount: $297702
Abstract
pending.
Personnel
Thummel, Kenneth E., Principal Investigator, Professor, Pharmaceutics • Calamia, Justina C., Other, Research Scientist/engineer 2, Pharmaceutics • Thornton, Timothy A., Co-Investigator, Associate Professor, Biostatistics • Rettie, Allan E., Co-Investigator, Professor, Medicinal Chemistry • Veenstra, David, Co-Investigator, Professor, Department of Pharmacy • Prasad, Bhagwat, Co-Investigator, Asst Professor Without Tenure, Pharmaceutics • Royall, Frederick, Administrative Contact, Grants And Contracts Manager/specialist, Pharmaceutics • Royall, Frederick, Budget Contact, Grants And Contracts Manager/specialist, Pharmaceutics • Royall, Frederick, eGC1 Preparer, Grants And Contracts Manager/specialist, Pharmaceutics
Persistent modulation of microbiota to enhance HIV vaccination
Klatt, Nichole , Pharmaceutics
Award Date: 12/19/2017
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Amount: $886469
Abstract
Here we propose a novel HIV vaccination approach that uses persistent probiotic therapy as an adjuvant to enhance immunogenicity and protection induced by a potent combined vaccine strategy. Our vaccine consists of concurrently administered SIV (gag p55) and HIV (gp140) DNA + HIV gp140 trimer protein. Recent studies have provided evidence that combining DNA and protein for vaccination elicits increased vaccine specific cellular and humoral immunity, In addition, our preliminary studies provocatively demonstrated that probiotic treatment in SIV-uninfected macaques results in increased T follicular helper cells in lymph nodes, IgA expressing B cells in mucosal tissues, increased antigen presenting cells in mucosal tissues, and increased multifunctional T cells, as well as decreased proliferation and activation of CD4+ T cells. Thus, we hypothesize that combining the potent immunomodulatory effects of beneficial microbiota manipulation with a novel vaccine platform that should induce robust cellular and humoral immunity will result in unprecedented high levels of vaccine specific responses in both mucosal and systemic tissues, resulting in protection from rectal SHIV challenge.
Personnel
Klatt, Nichole, Principal Investigator, Asst Professor Without Tenure, Pharmaceutics • Manuzak, Jennifer, Other, Senior Fellow, Pharmaceutics • Fuller, Deborah, Co-Investigator, Assoc Professor Without Tenure, Microbiology • Royall, Frederick, Administrative Contact, Grants And Contracts Manager/specialist, Pharmaceutics • Royall, Frederick, Budget Contact, Grants And Contracts Manager/specialist, Pharmaceutics • Royall, Frederick, eGC1 Preparer, Grants and Contracts Manager/Specialist, PCEUT - A, Pharmaceutics
The University of Washington, School of Pharmacy Research Affiliates Program on Transporters (UWRAPT)
Unadkat, Jashvant D , Pharmaceutics
Award Date: 12/13/2017
Sponsor: Pfizer, Inc. Amount: $60000
Abstract
The goal of this project is to establish a Research Affiliates Program at the UW within the School of Pharmacy. The RAP will bring together UW researchers and industry partners interested in furthering research to elucidate and quantify the role of transporters in the absorption, disposition, efficacy and toxicity of drugs..
Personnel
Unadkat, Jashvant, Principal Investigator, Professor, Pharmaceutics • Rogers, Catherine Cole, Other, Fiscal Specialist 1, Pharmaceutics • Royall, Frederick, Administrative Contact, Grants and Contracts Manager/specialist, Pharmaceutics • Eng, Matthew N., Budget Contact, Administrator, Pharmaceutics • Royall, Frederick, eGC1 Preparer, Grants and Contracts Manager/specialist, Pharmaceutics • Chau, Alvin, Budget Preparer, Budget/fiscal Analyst Lead, Pharmaceutics
Estimating the Economic Impact of Pre-Diagnosis Health Care Resource Use in Patients with Infantile Spasms
Hansen, Ryan , Department of Pharmacy
Award Date: 12/12/2017
Sponsor: Mallinckrodt, Inc. Amount: $59632
Abstract
Specific AimsThis study is comprised of three specific aims:1) Describe the healthcare resource use and treatment patterns of IS patients in the 90 days prior to the first IS diagnosis.2) Compare the 90-day pre-diagnosis resource use and treatment patterns of IS patients who receive Acthar to those who receive Sabril.3) Disseminate prior and current findings on the use of H.P. Acthar Gel in Neurologic Disorders in the form of two scientific manuscripts.
Personnel
Hansen, Ryan, Principal Investigator, Research Assistant Professor, Department of Pharmacy • Weatherford, Sally, Administrative Contact, Administrator, Department of Pharmacy • Luetjen, Karen H., Budget Contact, Grants And Contracts Manager/specialist, Pharm - A, Department of Pharmacy • Luetjen, Karen H., eGC1 Preparer, Grants And Contracts Manager/specialist, Pharm - A, Department of Pharmacy
Rational Integration of clinical SEquencing (RISE)
Veenstra, David , Department of Pharmacy
Award Date: 12/06/2017
Sponsor: Vanderbilt University Medical Center Amount: $186096
Abstract
The University of Washington subcontract will be directed by Dr. David Veenstra, who will be responsible for developing cost effectiveness models for genomic sequencing. Dr. Veenstra will have responsibility for all administrative and scientific activities conducted at University of Washington. He will oversee study personnel and will ensure completion of all study activities. Dr. Veenstra will supervise the work of the senior scientist and a graduate student research assistant.
Personnel
Veenstra, David, Principal Investigator, Professor, Department of Pharmacy • Weatherford, Sally, Administrative Contact, Administrator, Department of Pharmacy • Luetjen, Karen H., Budget Contact, Grants And Contracts Manager/specialist, Pharm - A, Department of Pharmacy • Ehlers, Sellyna A, eGC1 Preparer, Grants And Contracts Manager/specialist, Department of Pharmacy • Ehlers, Sellyna A, Budget Preparer, Grants And Contracts Manager/specialist, Department of Pharmacy
Effectiveness of Gastric Sleeve vs. Gastric Bypass for Cardiovascular Disease Y2
Basu, Anirban , Department of Pharmacy
Award Date: 12/04/2017
Sponsor: Kaiser Permanente Amount: $207080
Abstract
Bariatric surgery is one of the most effective treatment strategies for weight loss in the severely obese. Currently, two operations constitute the majority of these procedures: Vertical Sleeve Gastrectomy (VSG), the newest restrictive procedure, in which only stomach size is reduced, and Roux-en-Y Gastric Bypass (RYGB), the ‘gold standard’ procedure, in which gastric capacity is similarly limited but with an additional modest bypass of a section of small intestine. From 2008-2011, there was a ~5-fold increase in use of VSG in North America (from 4% to 19%); in contrast, use of RYGB declined from 51% to 47%. If trends continue, VSG may comprise up to 50% or more of all bariatric procedures by 2020. The reasons for this dramatic shift in procedural preference are unknown, but it is likely due to the perception of surgeons that VSG and RYGB are at clinical equipoise, but VSG is easier to perform, less expensive, and has fewer complications. A clear evidence base to support these perceptions does not exist. Current clinical knowledge suffers from two major gaps. GAP 1: Very few studies have included many important cardiovascular health outcomes. Comparative changes with RYGB and VSG in prevalent cardiovascular disease (CVD) risk factors such as hypertension and dyslipidemia, as well as overall CVD risk, have not been studied. There is also almost nothing known about the comparative safety of VSG and RYGB beyond the standard reporting period of 30 days after surgery. GAP 2: Almost nothing has been published regarding the heterogeneity in comparative effectiveness and safety between these two procedures. Even among the few small published comparative studies, there is no understanding of how heterogeneity in effects might determine which procedure is most appropriate for certain kinds of patients. Our own preliminary work clearly shows that racial/ethnic minority patients have different weight loss responses to RYGB (losing less weight) but similar responses to VSG (no difference in weight loss), compared to whites. Given these major gaps in knowledge, large-scale comparative effectiveness studies, using real-world clinical populations are urgently needed to improve bariatric treatment decision-making for severely obese patients, especially with respect to CVD outcomes. We have designed such a study to compare the effectiveness of VSG and RYGB for hypertension, dyslipidemia, and diabetes remission as well as overall CVD risk reduction in more than 17,000 VSG and 11,000 RYGB patients, from a real-world health care setting with an integrated electronic medical record. This combined sample size is over 20 times the number of VSG and RYGB patients that have been directly compared in case series and controlled trials to date (n = 1,041). No other studies in the literature have the diversity of bariatric surgery patients in our sample, who are 56% Hispanic or non-Hispanic Black. We will apply innovative econometric techniques to deal with selection biases in observation data and study heterogeneity in effects to inform clinical knowledge and identify areas where further studies are needed. We have assembled an experienced, interdisciplinary research and clinical care team to address the following specific aims over a median three years of follow-up.
Personnel
Basu, Anirban, Principal Investigator, Professor, Department of Pharmacy • Khandelwal, Saurabh, Key Personnel, Asst Professor Without Tenure, Surgery • Weatherford, Sally, Administrative Contact, Administrator, Department of Pharmacy • Luetjen, Karen H., Budget Contact, Grants And Contracts Manager/specialist, Department of Pharmacy • Weatherford, Sally, eGC1 Preparer, Administrator, Department of Pharmacy
Sunovion Study
Haliski, Melissa , Department of Pharmacy
Award Date: 12/04/2017
Sponsor: Sunovion Pharmaceuticals Inc. Amount: $94465
Abstract
The overall study objective is to evaluate the acute anticonvulsant activity of investigational compounds in rodent models of seizure.
Personnel
Haliski, Melissa, Principal Investigator, Research Assistant Professor, Department of Pharmacy • White, Harold Steve, Key Personnel, Professor, Department of Pharmacy • Weatherford, Sally, Administrative Contact, Administrator, Department of Pharmacy • Luetjen, Karen H., Budget Contact, Grants And Contracts Manager/specialist, Department of Pharmacy • Luetjen, Karen H., eGC1 Preparer, Grants And Contracts Manager/specialist, Department of Pharmacy
Optimizing Busulfan: Efficacy, Toxicity, and Pharmacometabolomics
Lin, Yvonne S. , Pharmaceutics
Award Date: 11/29/2017
Sponsor: City of Hope National Medical Center Amount: $120836
Abstract
Dr. Lin will oversee the activities of the UW Pharmacokinetics Laboratory (PK Lab). The UW PK Lab staff will collect samples from clinical trial participants, quantitate those samples for select busulfan metabolites (i.e., tetrahydrothiophenium ion (THT+), THT+ 1-oxide, sulfolane, and 3-hydroxysulfolane) and communicate those results to the Dr. McCune at City of Hope and Dr. Baker at Fred Hutch.
Personnel
Lin, Yvonne S., Principal Investigator, Associate Professor, Pharmaceutics • Phillips, Brian, Other, Research Scientist/engineer 3, Pharmaceutics • Shireman, Laura M., Other, Research Coordinator, Pharmaceutics • Men, Alex J, Other, Student Assistant, Pharmaceutics • Royall, Frederick, Administrative Contact, Grants and Contracts Manager/specialist, Pharmaceutics • Royall, Frederick, Budget Contact, Grants and Contracts Manager/specialist, Pharmaceutics • Royall, Frederick, eGC1 Preparer, Grants and Contracts Manager/specialist, Pharmaceutics
UW Patient Centered Outcomes Research Institutional Mentored Career Development Program (K12)
Sullivan, Sean , Department of Pharmacy
Award Date: 11/20/2017
Sponsor: Agency for Healthcare Research and Quality (AHRQ) Amount: $344099
Abstract
This program aims to develop early career scientists in PCOR evidence development, adoption and evaluation. At the completion of their training, Scholars will have cutting edge PCOR skills and a grounding in implementation and dissemination science. Our overall aims are to (1) provide Scholars with multidisciplinary training, (2) activate Scholars to utilize existing and unparalleled opportunities within the UW and affiliated institutions to learn PCOR and CER from experts with ongoing projects, multidisciplinary teams, data resources, and real world populations and stakeholders, (3) create an environment that supports the early research efforts of junior faculty, infuses them with the excitement of comparative effectiveness research and nurtures their early career development and productivity and aids in ensuring a long term career in conducting and teaching PCOR.
Personnel
Sullivan, Sean, Principal Investigator, Professor, Department of Pharmacy • Devine, Emily E., Mentor, Associate Professor, Department of Pharmacy • Patrick, Donald L., Mentor, Professor, Health Services/Main • Weatherford, Sally, Administrative Contact, Administrator, Department of Pharmacy • Kraegel, Paul K., Budget Contact, Program Operations Specialist, Department of Pharmacy • Kraegel, Paul K., eGC1 Preparer, Program Operations Specialist, Department of Pharmacy
PHPDA/SHAG Prevention of Medical Mishaps
Downing, Donald F , Department of Pharmacy
Award Date: 11/17/2017
Sponsor: Senior Housing Assistance Group (SHAG) Amount: $11300
Abstract
The Senior Housing Assistance Group (SHAG) has received a grant through the Pacific Hospital Preservation and Development Authority (PHPDA) with the support of the PI and the UW Department of Pharmacy. The PI and project team will help the sponsor examine the unmet healthcare and social needs of SHAG residents and to develop an informed long-term strategy to keep these residents in their homes, living independently as long as possible.
Personnel
Downing, Donald F, Principal Investigator, Endowed Faculty Fellowship in Innovative Pharmacy, Department of Pharmacy • Weatherford, Sally, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, Department of Pharmacy • Luetjen, Karen H., Budget Contact, Grants And Contracts Manager/specialist, Pharm - A, Department of Pharmacy • Luetjen, Karen H., eGC1 Preparer, Grants And Contracts Manager/specialist, Pharm - A, Department of Pharmacy
Oral contraceptive drug interactions
Isoherranen, Nina , Pharmaceutics
Award Date: 11/13/2017
Sponsor: GlaxoSmithKline, Inc. Amount: $49992
Abstract
The objective of this project is to develop a Physiologically based pharmacokinetic (PBPK) model (either using simcyp or matlab) for the most common estrogen and progestin oral contraceptives to allow prediction of clinical drug-drug interactions (DDIs) with select oral contraceptives (OC's). The model development will establish the scope of experimental wet lab work that will need to be done to truly validate a model so it can be used for clinical DDI prediction.
Personnel
Isoherranen, Nina, Principal Investigator, Professor, Pharmaceutics • Shum, Hiu M, Other, Predoctoral Research Associate 2, PCEUT - ISOHERRA, Pharmaceutics • Royall, Frederick, Administrative Contact, Grants and Contracts Manager/Specialist, PCEUT - A, Pharmaceutics • Royall, Frederick, Budget Contact, Grants and Contracts Manager/Specialist, PCEUT - A, Pharmaceutics • Royall, Frederick, eGC1 Preparer, Grants and Contracts Manager/Specialist, PCEUT - A, Pharmaceutics
Sunovion Study
Haliski, Melissa , Department of Pharmacy
Award Date: 11/08/2017
Sponsor: Sunovion Pharmaceuticals Inc. Amount: $9750
Abstract
The overall study objective is to evaluate the acute anticonvulsant activity of investigational compounds in rodent models of seizure.
Personnel
Haliski, Melissa, Principal Investigator, Research Assistant Professor, Department of Pharmacy • White, Harold Steve, Key Personnel, Professor, Department of Pharmacy • Weatherford, Sally, Administrative Contact, Administrator, Department of Pharmacy • Luetjen, Karen H., Budget Contact, Grants And Contracts Manager/specialist, Department of Pharmacy • Luetjen, Karen H., eGC1 Preparer, Grants And Contracts Manager/specialist, Department of Pharmacy
Inter-species differences in kidney drug transporter abundance
Prasad, Bhagwat , Pharmaceutics
Award Date: 11/01/2017
Sponsor: Pfizer, Inc. Amount: $55000
Abstract
A validated liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) proteomics assay will be used to simultaneously quantify changes in ~20 kidney cortex transporters across multiple toxicological species and humans. This approach uses a triple quadrupole MS instrument to achieve selectivity by quantifying specific daughter ions generated from surrogate peptides of the transporter protein (Prasad DMD, 2016; Vrana CPT:PSP, 2017). This allows multiplexed quantification of proteins in a complex sample without prior isolation and is not limited by the availability or quality of antibodies.
Personnel
Prasad, Bhagwat, Principal Investigator, Assistant Professor without Tenure, Pharmaceutics • Karasu, Matthew Thomas, Other, Project Appointment - Overtime Exempt, PCEUT - PRA, Pharmaceutics • Bhatt, Deepak Kumar, Co-Investigator, Senior Fellow, Pharmaceutics • Royall, Frederick, Administrative Contact, Grants and Contracts Manager/Specialist, PCEUT - A, Pharmaceutics • Royall, Frederick, Budget Contact, Grants and Contracts Manager/Specialist, PCEUT - A, Pharmaceutics • Royall, Frederick, eGC1 Preparer, Grants and Contracts Manager/Specialist, PCEUT - A, Pharmaceutics
Impact of Malaria Co-Infection on HIV Vaccination
Klatt, Nichole , Pharmaceutics
Award Date: 10/26/2017
Sponsor: National Institutes of Health (NIH) Amount: $349968
Abstract
HIV and malaria are two of the most devastating infectious diseases in the world. In 2015, these diseases together caused over 1.4 million deaths. Although advances have been made in preventing new infections of both HIV and malaria, the risk of infection with either disease in the world’s poorest nations is still great. Furthermore, as HIV and malaria are endemic to similar geographical areas, this overlap constitutes great risk for co-infection of individuals, which could fuel the spread of both diseases. Moreover, HIV and malaria infection have been shown to cause similar gastrointestinal pathologies, including disruption of the epithelial barrier and altered intestinal immune function. As infection across the rectal mucosa constitutes a major route for sexual transmission of HIV, it is possible that prior infection with malaria could increase the risk of acquisition of HIV, should exposure of this mucosal membrane occur. Importantly, as the biomedical research field moves closer to the development of an effective vaccine to prevent new HIV infections, it will be critical to take into account alterations in mucosal phenotype and function that may occur due to malaria infection, as these changes could impact the efficacy of the HIV vaccine. Here, we aim to determine how concurrent malaria infection could alter the efficacy of SHIV vaccination in rhesus macaques. We will assess immunological and microbial alterations in the intestinal mucosa during malaria infection and track these changes throughout subsequent SHIV vaccination and SHIV challenge, in order to elucidate how malaria may alter HIV vaccine responses and thus diminish protection from SHIV infection. These studies will generate critical knowledge of the impact of malaria on HIV vaccination strategies, which will aid in the development of vaccines that take into account environmental factors such as other co-endemic infectious diseases, and thus be effectively employed in the developing world, where the need for an HIV vaccine is the greatest.
Personnel
Klatt, Nichole, Principal Investigator, Asst Professor Without Tenure, Pharmaceutics • Manuzak, Jennifer, Key Personnel, Senior Fellow, Pharmaceutics • Royall, Frederick, Administrative Contact, Grants And Contracts Manager/specialist, Pharmaceutics • Royall, Frederick, Budget Contact, Grants and Contracts Manager/specialist, Pharmaceutics • Royall, Frederick, eGC1 Preparer, Grants and Contracts Manager/specialist, Pharmaceutics
Natural Product-Drug Interaction Research: The Roadmap to Best Practices
Thummel, Kenneth E. , Pharmaceutics
Award Date: 10/23/2017
Sponsor: Washington State University (WSU) Amount: $384360
Abstract
Administrative CoreThe Administrative Core under the parent grant has a two-fold responsibility. At the program level, the Administrative Core coordinates the basic administrative and financial services to the Cores and participating institutions. At the project level, the Administrative Core is charged with 1) supporting the oversight Steering Committee in monitoring and approving selection of the priority NPs and completion of the Statements of Work (SOWs) by the Pharmacology Core; 2) participating in the Interaction Project teams to monitor progress and the transfer of samples and data to the Analytical and Pharmacology Cores, respectively; 3) developing and disseminating the Recommended Approaches (RAs); and 4) coordinating with the Informatics Core to develop and maintain the web portal to allow public access to Best Practices and archived data from the Interaction Projects.The Administrative Core component of this subcontract supports the effort of Dr. Danny Shen (Co-I). Dr. Shen, who formerly was the PI of the U54 grant before he assumed semi-retirement in September of 2016, will mainly provide advice and counsel for the first three elements of the programmatic function of the Administrative Core, namely design and construction of the SOWs, execution of the Interaction Projects, and development of the RAs.Pharmacology CoreFor the remaining 3-year period of the parent grant, the Pharmacology Core has the principal responsibility of designing and guiding the implementing the Interaction Projects through the development of SOWs. The development path begins with a carefully orchestrated set of preclinical studies on selected natural product-drug interactions (NPDIs) and ends with a definitive assessment of the risk or safety of the NPDIs, or the need for further investigation. Using rigorous, predefined decision trees as guides, detailed SOWs for the selected NPDIs will be developed. These SOWs represent key deliverables of this Core and will be used subsequently to develop RAs for NPDI research.The Pharmacology Core component of this subcontract supports the efforts of Dr. Allan Rettie (Co-I) and Dr. Jashvant Unadkat (Co-I), two preeminent translational and clinical pharmacologist. The two Co-I will work with the PI of the parent grant, Dr. Mary Paine in developing the SOWs for the three selected priority natural products: green tea, goldenseal and cannabis. UW portion of the Pharmacology Core will conduct all the necessary preclinical studies for identifying potential drug interactions with cannabis extracts and its constituent cannabinoids. At present, the preclinical studies will largely consist of validated in vitro screening assays for known drug metabolizing enzymes and drug transporters. Bench support will be provided by a qualified postdoctoral fellow, Dr. Neha Maharao.Analytical CoreUnder the parent grant, the Analytical Core is charged with 1) characterizing the bioactive constituents of the priority natural products selected for the Interaction Projects, 2) synthesizing and supplying the purified bioactive constituents for preclinical studies on drug interaction potentials, and 3) supporting the analysis of samples generated from both the preclinical and human subject studies under the Interaction Projects.The Analytical Core component of this subcontract will focus on the third charge, mainly to provide the critical analytical support for the preclinical studies on standardized cannabis extracts obtained from National Institute on Drug Abuse (NIDA) in regards to their potential for modulating drug metabolizing enzymes and drug transporters. The analysis tasks will consist of development of sensitive and specific mass-spectrometry based assays for the cannabinoid constituents present in the cannabis extracts (i.e., the perpetrators) and the drug and/or metabolites of the probes used in the enzyme or transporter screens. All assays will be performed in our shared research resource PK Lab in the Department of Pharmaceutics.A secondary assignment for the UW component of the Analytical Core is to provide back-up support or overflow capacity in the analysis of biological samples (i.e., blood/plasma and urine) collected from human subject studies under the Interaction Projects. At present, the analyses are being handled by Dr. Mary Paine’s laboratory at WSU. UW PK Lab will provide back-up LC-MS/MS support on those occasions when the WSU LC-MS facility develops major instrumentation problems. The PK Lab will also handle overflow samples from WSU according well-defined Standard Operating Procedures (SOPs).
Personnel
Thummel, Kenneth E., Principal Investigator, Professor, Pharmaceutics • Maharao, Neha, Other, Senior Fellow, Pharmaceutics • Phillips, Brian, Other, Research Scientist/engineer 3, Pharmaceutics • Shen, Danny D, Co-Investigator, Professor Emeritus, Pharmaceutics • Unadkat, Jashvant D, Co-Investigator, Professor, Pharmaceutics • Rettie, Allan E., Co-Investigator, Professor, Medicinal Chemistry • Royall, Frederick, Administrative Contact, Grants and Contracts Manager/specialist, Pharmaceutics • Royall, Frederick, Budget Contact, Grants and Contracts Manager/specialist, Pharmaceutics • Royall, Frederick, eGC1 Preparer, Grants and Contracts Manager/specialist, Pharmaceutics
Screening of Investigational Compounds to Treat, Modify or Prevent Epilepsy for the NINDS Epilepsy Therapy Screening Program (ETSP)
White, Harold Steve , Department of Pharmacy
Award Date: 10/20/2017
Sponsor: University of Utah Amount: $255660
Abstract
The systemic kainic acid (KA)-induced status epilepticus (SE) model in rats is an etiologically-relevant animal model of epileptogenesis. All of the clinical characteristics observed in human patients with temporal lobe epilepsy (TLE) are also observed in the rat systemic KA model of SE and TLE. Moreover, the systemic low-dose KA paradigm is ideally suited for preclinical drug screening studies to evaluate the long-term process of epileptogenesis. As a first attempt to identify novel and potentially efficacious antiepileptogenic agents, it is necessary to define whether administration of the investigational compound during the SE insult or immediately after (e.g. during the latent period) can first modify presentation and severity of spontaneous recurrent seizures, as well as attendant comorbidities, in the rat KA-SE model of epileptogenesis. The goal of the proposed studies is to determine whether administration of promising investigational anticonvulsant compounds can also modify or attenuate the presentation of spontaneous recurrent seizures days to weeks after SE, as well as modify the SE-induced behavioral deficits associated with TLE.
Personnel
Stergachis, Andreas S, Principal Investigator, Professor, Department of Pharmacy • Weatherford, Sally, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, Department of Pharmacy • Luetjen, Karen H., Budget Contact, Grants and Contracts Manager/Specialist, Pharm - A, Department of Pharmacy • Luetjen, Karen H., eGC1 Preparer, Grants and Contracts Manager/Specialist, Pharm - A, Department of Pharmacy
Optimizing Busulfan: Efficacy, Toxicity, and Pharmacometabolomics
Lin, Yvonne S. , Pharmaceutics
Award Date: 10/20/2017
Sponsor: City of Hope National Medical Center Amount: $64280
Abstract
Dr. Lin will oversee the activities of the UW Pharmacokinetics Laboratory (PK Lab). The UW PK Lab staff will collect samples from clinical trial participants, quantitate those samples for select busulfan metabolites (i.e., tetrahydrothiophenium ion (THT+), THT+ 1-oxide, sulfolane, and 3-hydroxysulfolane) and communicate those results to the Dr. McCune at City of Hope and Dr. Baker at Fred Hutch.
Personnel
Lin, Yvonne S., Principal Investigator, Associate Professor, Pharmaceutics • Phillips, Brian, Other, Research Scientist/engineer 3, Pharmaceutics • Shireman, Laura M., Other, Research Coordinator, Pharmaceutics • Men, Alex J, Other, Student Assistant, Pharmaceutics • Royall, Frederick, Administrative Contact, Grants and Contracts Manager/specialist, Pharmaceutics • Royall, Frederick, Budget Contact, Grants and Contracts Manager/specialist, Pharmaceutics • Royall, Frederick, eGC1 Preparer, Grants and Contracts Manager/specialist, Pharmaceutics
WWARN Malaria Elimination Safety Study Group
Stergachis, Andreas S , Department of Pharmacy
Award Date: 10/18/2017
Sponsor: Liverpool School of Tropical Medicine Amount: $7077
Abstract
The University of Washington will work with the Liverpool School of Tropical Medicine, Oxford University’s WorldWide Antimalarial Resistance Network (WWARN), and the University of California-San Francisco’s Malaria Elimination Initiative to establish a global study group focused on assessment of the safety of single low-dose primaquine. Eventually, a pooled analysis of the safety of single low-dose primaquine to interrupt P. falciparum will be conducted under the auspices of WWARN.
Personnel
Stergachis, Andreas S, Principal Investigator, Professor, Department of Pharmacy • Weatherford, Sally, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, Department of Pharmacy • Luetjen, Karen H., Budget Contact, Grants and Contracts Manager/Specialist, Pharm - A, Department of Pharmacy • Luetjen, Karen H., eGC1 Preparer, Grants and Contracts Manager/Specialist, Pharm - A, Department of Pharmacy
Time and Dose-Response in PTZ Challenge Model
White, Harold Steve , Department of Pharmacy
Award Date: 10/05/2017
Sponsor: Takeda California, Inc. (TCAL) Amount: $4750
Abstract
Two investigational compounds (SYR273841, SYR268663) will be screened for dose- and time-dependent efficacy in the intravenous (i.v.) pentylenetetrazol model of seizure threshold in male CF-1 mice.
Personnel
White, Harold Steve, Principal Investigator, Chair, Department of Pharmacy • Weatherford, Sally, Administrative Contact, Administrator, Department of Pharmacy • Luetjen, Karen H., Budget Contact, Grants And Contracts Manager/specialist, Department of Pharmacy • Ehlers, Sellyna A, eGC1 Preparer, Grants And Contracts Manager/specialist, Department of Pharmacy • Ehlers, Sellyna A, Budget Preparer, Grants And Contracts Manager/specialist, Department of Pharmacy
CDA for OVID Therapeutics
Haliski, Melissa , Department of Pharmacy
Award Date: 10/04/2017
Sponsor: Ovid Therapeutics Amount: $57650
Abstract
Major goal is: To quantify the dose-dependent ability of allopregnanolone (ALLO), ganaxalone (GNX), and gaboxadol (GBX) to halt benzodiazepine-resistant lithium-pilocarpine (Li-Pilo)-induced SE in rats.
Personnel
Haliski, Melissa, Principal Investigator, Research Assistant Professor, Department of Pharmacy • White, Harold Steve, Key Personnel, Professor, Department of Pharmacy • Weatherford, Sally, Administrative Contact, Administrator, Department of Pharmacy • Luetjen, Karen H., Budget Contact, Grants And Contracts Manager/specialist, Department of Pharmacy • Weatherford, Sally, eGC1 Preparer, Administrator, Department of Pharmacy
Assessment of quality of liver subcellular fractions as in vitro models of drug metabolism
Prasad, Bhagwat , Pharmaceutics
Award Date: 10/03/2017
Sponsor: Genentech, Inc. Amount: $50000
Abstract
In vitro drug metabolism data obtained in the enriched subcellular fractions such as microsomes and cytosol derived by differential centrifugation are commonly utilized for the in vitro to in vivo extrapolation (IVIVE) of drug clearance. The purity of subcellular fractions and the accurate estimation of physiologically relevant scaling factor, i.e., microsomal or cytosolic protein per gram of tissue, are the key parameters in the implementation of IVIVE. Further, while the localizations of traditional hepatic DMEs (CYPs, UGTs) are well characterized, localization of other DMEs including carboxylesterases (CESs), AOX, paraoxonases (PONs), etc., is not well known. This knowledge gap is a major limitation in in the IVIVE of non-CYP mediated drug clearance.
Personnel
Prasad, Bhagwat, Principal Investigator, Assistant Professor without Tenure, Pharmaceutics • Vrana, Marc A, Other, PREDOCTORAL RESEARCH ASSOCIATE 2, PCEUT - PRASAD L, Pharmaceutics • Royall, Frederick, Administrative Contact, Grants and Contracts Manager/Specialist, PCEUT - A, Pharmaceutics • Royall, Frederick, Budget Contact, Grants and Contracts Manager/Specialist, PCEUT - A, Pharmaceutics • Royall, Frederick, eGC1 Preparer, Grants and Contracts Manager/Specialist, PCEUT - A, Pharmaceutics
Maternal Immunization Pharmacovigilance in Low and Middle-Income Countries
Stergachis, Andreas S , Department of Pharmacy
Award Date: 10/02/2017
Sponsor: Global Alliance to Prevent Prematurity and Stillbirth (GAPPS) Amount: $12331
Abstract
Vaccination programs represent a cornerstone of public health, and have resulted in cost-effective global health strategies that have prevented disease, death, and disability worldwide, including among pregnant women and newborns. Extensive work has gone into the field of pharmacovigilance for low- and middle-income country (LMIC) settings, but not for vaccination programs in pregnant women. This project, commissioned by the Bill & Melinda Gates Foundation to the Global Alliance to Prevent Prematurity and Stillbirth (GAPPS), an Initiative of Seattle Children's, will consist of conducting a review of existing scientific literature, guidelines, and programs relevant to vaccine safety and, through adaptation of this existing body of work and in partnership with key experts and stakeholders worldwide, build a strategic framework for maternal immunization pharmacovigilance systems in LMIC. The UW principal investigator is requested by GAPPS to serve as a technical expert and one of the lead authors of the report, contributing specifically to topic areas related to pharmacovigilance systems in LMICs.
Personnel
Stergachis, Andreas S, Principal Investigator, Professor, Department of Pharmacy • Brase, Jessica E., Administrative Contact, Administrator, Department of Pharmacy • Luetjen, Karen H., Budget Contact, Grants And Contracts Manager/specialist, Pharm - A, Department of Pharmacy • Ehlers, Sellyna A, eGC1 Preparer, Grants And Contracts Manager/specialist, Department of Pharmacy